3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Adenocarcinoma
1
Interventions
Gemcitabine
8
pembrolizumab
5
Paclitaxel
4
Capecitabine
4
Albumin-Bound Paclitaxel
4
Nivolumab
3
Fluorouracil
3
Cyclophosphamide
3
Carboplatin
3
sargramostim
2
poly ICLC
2
fludarabine
2
Prednisone
2
Oxaliplatin
2
Irinotecan
2
Hydroxychloroquine
2
Erlotinib Hydrochloride
2
Dexamethasone
2
Cisplatin
2
130-nm albumin-bound paclitaxel
2
temsirolimus
1
tegafur-gimeracil-oteracil
1
spartalizumab
1
sintilimab
1
rucaparib
1
resiquimod
1
repotrectinib
1
regorafenib
1
pralsetinib
1
olaparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Adenocarcinoma
×
tegafur-gimeracil-oteracil
×
Clear all
NCT02564367
2021-04-29
S-1 adjuvant
AIO-Studien-gGmbH
Phase 1/2
Completed
30 enrolled